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Abstract
Background: Planning the surgical strategy for a gastrointestinal stromal tumor (GIST) at the posterior wall of the
lower rectum is difficult, as the procedures for the lower rectum are hampered by poor visualization and may cause
anal dysfunction or discomfort. We report a novel procedure to resect a submucosal tumor of the rectum.
Case presentation: A 75-year-old woman presented with metrorrhagia. Endovaginal ultrasonography showed a
low echoic tumor. Computed tomography showed an enhanced tumor, measuring 5.3 × 4.2 cm, behind the
rectum. Magnetic resonance imaging revealed a submucosal tumor of the rectum, measuring 5.3 cm at its
greatest dimension. Colonoscopy showed that the distal tumor margin was 1 cm above the dentate line. Core
needle biopsy of the tumor revealed the rectal GIST. After receiving neoadjuvant imatinib treatment, the tumor
size decreased to 3.5 cm. During the operation, we approached the rectum and resected the posterior rectal wall,
including the 3.5 × 3.5 cm tumor with a safety margin, making an arched incision at the buttocks to form a skin
flap with the patient in a jackknife position. The histopathological diagnosis was GIST of the rectum. Her anorectal
sphincter function was well preserved. No recurrence was seen during the 2-year follow-up.
Conclusions: This novel approach improves the operative field visibility in resecting a tumor with a safety margin
and preserves a patient’s anorectal sphincter function.
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Background
Gastrointestinal stromal tumors (GISTs) occur most
often in the stomach (60%) and the small intestine (35%)
[1]. GISTs of the colon and rectum constitute <5% of all
cases and occur more often in the rectum [2]. Surgery
with histologically negative margins is the recommended
primary treatment for nonmetastatic GISTs [3]. Neoadju-
vant therapy of imatinib, a selective tyrosine kinase inhibi-
tor, for rectal GISTs, with the aim of preserving the anus,
is still a challenging therapy that typically takes several
months [4]. Planning the surgical strategy for a GIST at
the posterior wall of the lower rectum is difficult, as the
procedures for the lower rectum are hampered by poor
visualization and may cause anal dysfunction or discom-
fort. We describe our experience with a patient who
underwent a novel approach, which improves the opera-
tive field visibility in resecting a tumor with a safety mar-
gin and preserves a patient’s anorectal sphincter function.
Case presentation
A 75-year-old woman with metrorrhagia visited a
gynecology clinic. Transvaginal ultrasound showed a
retroperitoneal tumor. She was referred to our hospital
for a detailed examination. The results of the laboratory
examinations were as follows: white blood cell count,
5660/mm3 (normal range 4500–9000); red blood cell count,
383 × 104/mm3 (normal range 435–555); hemoglobin
level, 12.5 g/dL (normal range 13.6–17.0); platelet count,
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26.8 × 104/mm3 (normal range 14.0–36.0); serum blood
urea nitrogen level, 18.6 mg/dL (normal range 8–20);
serum creatinine level, 0.46 mg/dL (normal range 0.5–
1.2); and tumor marker levels were within the normal
ranges (carcinoembryonic antigen, 3.9 ng/mL and CA,
19–9 2.0 U/mL). The laboratory data were within normal
limits, instead of demonstrating them. She had no history
of serious illnesses, operations, or hospitalizations. Com-
puted tomography (CT) showed an enhanced tumor,
measuring 5.3 × 4.2 cm, behind the rectum (Rb) (Fig. 1a
and c). Pelvic magnetic resonance imaging (MRI) detected
a well-defined tumor with low T1 and high T2 intensities
(Fig. 2a, b). Colonoscopic examination revealed that a sub-
mucosal tumor at the posterior rectal wall, and that the
distal tumor margin was 1 cm above the dentate line
(Fig. 2c). Core needle biopsy of the tumor revealed bun-
dles of spindle cells with positive immunohistochemical
staining for c-kit and CD34, but negative for S100 pro-
teins. The pathological findings led to the diagnosis of a
rectal GIST. Neoadjuvant therapy was initiated with
imatinib 400 mg orally daily to reduce the resection range.
The therapy was scheduled for 6 months and would be
followed by surgical removal of the remaining tumor. CT
at 1 month after starting chemotherapy showed that the
tumor size had decreased to 4.5 cm. Unfortunately,
4 months after the initiation of neoadjuvant therapy, the
patient developed generalized erythematous papules with
severe itching. CT examination and colonoscopy revealed
that the tumor size had decreased to 3.5 × 3.5 cm (Figs. 1b,
d, and 2d). The patient underwent a partial sphincter-
saving rectal resection with creation of an ileostomy.
The patient was placed in a prone jackknife position
on the operating table, with the legs slightly abducted
and the buttocks strapped apart using adhesive tapes
from the buttocks to the table (Fig. 3a). First, the skin
flap was made by a cluneal arched skin incision between
the subcutaneous fat and lavatory muscle. We then
approached the posterior rectal wall through the side of
the gluteus maximus muscle and lavatory muscle of the
anus. The Waldeyer’s fascia was incised to expose the
tumor and the bared rectal wall. The tumor, lifted via
digital rectal examination, was extracted with a safety
margin (Fig. 3b, d, and e). The rectal wall was closed
using the Gambee’s method (absorbable suture), with
suturing of the muscle layer (3–0 silk) (Fig. 3c). A 19-Fr.
soft silastic tube drain was placed near the suture line,
and port site closure was completed. A temporary ileos-
tomy was created via laparoscopic surgery.
Histopathological examination revealed that the tumor
was located in the muscularis of the rectum, with a
negative margin (Fig. 4a), and had widespread central
necrosis via effective response from imatinib (Fig. 4b).
Microscopic examination showed the tumor was con-
sisted of bundle-like proliferations of spindle-shaped
cells (Fig. 4c). The immunohistological findings showed
that the tumor cells stained negatively with S100 and
SMA and positively with c-kit and CD34; the tumor was
diagnosed to be a KIT-positive GIST (Fig. 4d). The
a b
c d
Fig. 1 a Coronal CT images showed an enhanced tumor measuring 5.3 × 4.2 cm behind the rectum. b After the treatment of imatinib, coronal
CT images revealed that the tumor size decreased to 3.5 cm. c Axial CT images showed an enhanced tumor at the right posterior side of the
rectum. d After treatment of imatinib, axial CT images revealed that the tumor size decreased to 3.5 cm
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postoperative course was uneventful, and the ileostomy
was closed 2 months later. Postoperative anal function
was preserved, and the operative scar was fine and in-
conspicuous (Fig. 5a and b). Neither local recurrence
nor distant metastasis was noted during the 2-year
follow-up without adjuvant therapy.
Discussion
GISTs are rare but are, nevertheless, the most common
mesenchymal neoplasms of the gastrointestinal tract.
Mazur and Clark first introduced the term GIST in 1983
that constitute around 1% of all primary gastrointestinal
cancers [5]. Specific mutations in the so-called KIT
a b
c d
Fig. 2 a T1-weighted MRI showed a low intensity tumor. b T2-weighted MRI showed a high intensity tumor. c Colonoscopic examination re-
vealed a submucosal tumor at the posterior rectal wall, and that the distal tumor margin was 1 cm above the dentate line. d Colonoscopic exam-





gluteus maximus muscle 
lavator muscle
b
Fig. 3 a The patient was placed in the jackknife position, with the buttocks parted by adhesive strapping. b This is the image of the tumor resection,
showing an opening of the rectum (arrow). c The rectal wall was closed using the Gambee’s method with suturing of the muscle layer. d The tumor,
lifted via digital rectal examination, was extracted with a safety margin. e This is the schema of Fig. 3b
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oncogene are the most common cause of the development
of this tumor [6]. They can be found in the stomach
(51%), jejunum and ileum (36%), and colon and rectum
(5–7%), but can also occur extra-gastrointestinally in the
mesentery or omentum in rare cases [7, 8]. Size and mi-
totic activity contribute to the risk estimation for “malig-
nant behavior” of GIST, according to the National Cancer
Institute (NCI) consensus classification [3, 4, 9]. Surgery
remains the therapy of choice for patients with primary
GISTs, with no evidence of metastasis and should be the
initial therapy if the tumor is technically resectable and as-
sociated with an acceptable morbidity risk [3]. The goal of
the operation is complete gross resection with a negative
microscopic margin (R0 resection) without bleeding and
rupture of the pseudocapsule [10]. Neoadjuvant imatinib
treatment is also an option to facilitate function-
preserving surgeries for tumors in the gastro-esophageal
junction and rectum [11, 12]. Imatinib Mesylate is an
orally administered competitive inhibitor of the tyrosine
kinase associated with the KIT protein (stem cell factor
receptor), ABL protein, and platelet derived growth factor
receptors. Many studies have shown the effectiveness of
imatinib in the treatment of GISTs since its first report in
2001 [13]. As for rectal GISTs, several reports demon-
strated that neoadjuvant imatinib treatment improved R0
resection rates and decreased the risk of postoperative
morbidity [11, 14]. In the National Comprehensive Cancer
Network guidelines, it is recommended that neoadjuvant
Fig. 4 a, b The resected tumor was 3.5 × 3.5 × 2.5 cm in size. The rubbery-hard tumor with widespread central necrosis was completely
capsulized. c Microscopic examination (hematoxylin-eosin staining, original magnification: ×400) revealed a formation of spindle-shaped cells.
d Immunohistochemical staining of the tumor cells for c-kit revealed strong positive findings
a b
Fig. 5 a The operative scar was fine and inconspicuous (arrow). b Colonoscopy was performed before closing the ileostomy. The examination
showed a fine scar (arrow) with no stenosis
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imatinib treatment should be considered if abdominoperi-
neal resection is necessary to achieve a negative resection
margin, or if the surgeon feels that multivisceral resection
may be required [15]. However, in the restricted space of
the pelvis, complete resection of a large rectal GIST is dif-
ficult and often necessitates abdominoperineal resection
or intersphincteric resection (ISR), with or without adja-
cent organ resection. Miettinen et al. reported the treat-
ment of 144 cases of anorectal GIST [2]. In this study, the
smaller tumors (≤2 cm) were typically treated by enucle-
ation only, excluding one case. Tumors that were 2–5 cm
were also usually treated with local excision. Large tumors
(>5 cm) were commonly removed by abdominoperineal
or anterior resection with impairment of the sphincter
function (15 primary cases and 2 cases for the treatment
of recurrence). There are some reports in the literature
describing transanal, transcoccygeal, and transvaginal
approaches for the local excision of GISTs located in the
lower rectum with the aim of decreasing the morbidity
rate. Transanal excision is the most minimally invasive
approach; however, there is a limit to the distance from
the dentate line. Koscinski et al. reported that transanal
excision is appropriate for lesions located at an average
distance of 3 cm from the dentate line [16]. Furthermore,
whether this procedure is possible is often dominated by
the physique of the patient. Bleday indicated that trans-
coccygeal excision was especially useful for lesions at the
posterior rectal wall and appropriate for lesions located at
an average distance of 5 cm from the dentate line [17].
However, transcoccygeal excision provides a poor field of
view because of its high morbidity rate, such as postopera-
tive fistula occurring in 21% of patients [18]. The choice
of local resection that preserves the anal function must re-
sult in a negative margin different from the conventional
extend operation.
In our case, the 5.3-cm sized tumor situated at the
posterior wall of the lower rectum and the distal tumor
margin was 1 cm above the dentate line. Neoadjuvant
imatinib therapy was scheduled for 6 months as the ref-
erences which reported, in randomized clinical studies,
the cumulative incidence of response almost reached a
plateau after treatment for 6–8 months, and disease pro-
gression occurred in some patients even in this period
[19, 20]. After the administration of imatinib, the tumor
size decreased to 3.5 cm. The possible operations for
selection were abdominoperineal resection, ISR, or local
resection. However, we avoided abdominoperineal resec-
tion and ISR to preserve her anal function. The tumor
was too large to select the transanal approach for local
resection. The typical operation using the posterior
approach for rectal tumors is the method reported by
Kraske [21]. This method has a straight-line incision be-
cause the surgical field view is poorer than that of ours.
On the other hand, the surgical field view is clear with
anal dysfunction by cutting the sphincter in Mason’s
method [22]. Finally, we chose the sphincter-saving oper-
ation using a cluneal arched skin incision, which has
already been reported in Japanese literature [23]. In this
case, we performed the operation on the basis of this lit-
erature [23]. It is easy to approach the puborectal muscle
and external anal sphincter by making a skin flap with an
arch-shaped incision at the buttocks. After splitting both
sides of the posterior rectum, the tumors lifted from the
inside of the rectum were resected with the safety margin.
The advantages of this method include preserving the anal
function and providing a clear view during the operation.
In addition, surgical site infection is prevented as the skin
incision in our method is far from the anus.
Conclusions
We describe our experience with the patient who under-
went a novel approach that improves the operative field
visibility in resecting a tumor with a safety margin and
preserves a patient’s anorectal sphincter function.
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